About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Although human activated protein C (APC) has been used for years in patients with severe sepsis, trials have shown a lack of efficacy for the product and an increased incidence of bleeding. As a result, further study is needed to determine which patients are appropriate candidates for APC therapy.
Cesar Alaniz, PharmD
Drug Class Review
Sitagliptin (Januvia) and saxagliptin (Onglyza) provide another option for type-2 diabetes. However, clinicians should consider the cost, the potential for hypoglycemia, and the modest efficacy associated with these agents.
Rolee Pathak, PharmD, RPh, BCPS; and Mary Barna Bridgeman, PharmD, RPh
Part 2: Regulatory and Safety Concerns and Proposed Governmental Policy Changes with Respect to Dietary Supplements
Despite the lack of data from trials of dietary supplements, reports of interactions with drugs are increasing. Proposed changes would enhance the FDA’s authority.
C. Lee Ventola, MS
Topics include sitagliptin (Januvia and Janumet), a combination tablet (Tribenzor), and an investigational agent (GFT505).
IncobotulinumtoxinA (Xeomin), indicated for cervical dystonia and blepharo- spasm, and ulipristal acetate (ella), an emergency contraceptive, are discussed.
Marvin M. Goldenberg, PhD, RPh, MS
It may take a village to help the nearly 73 million Americans with hypertension. A report from the Institute of Medicine recommends ways to reduce risks, improve medication adherence, and increase funding for prevention and wellness programs.
David B. Nash, MD, MBA
Even though infusion pumps might be “smart,” they are useless unless clinicians take appropriate safety measures.
Matthew Grissinger, RPh, FASCP
The FDA is trying to figure out how to force drug companies to state the risks of their drugs more clearly and conspicuously in TV and radio ads.
FDA approvals, drug indications, product recalls, and industry updates.
The First Once-Daily Incretin Mimetic Injection for Type-2 Diabetes
Liraglutide (Victoza), a once-daily incretin mimetic injection for type-2 diabetes
Sylvia H. Jackson, PharmD, CDE, MEd; Tonya S. Martin, PharmD, CGP, MAEd; Jocelyn D. Jones, PharmD, BCPS; David Seal, PharmD, MS; and Frank Emanuel, PharmD